My Cart

Close
CARDIO NAD+
CARDIO NAD+
CARDIO NAD+
CARDIO NAD+

Healthgevity

CARDIO NAD+

$162.00

or 6 weekly interest-free payments of $27.00 Laybuy What's this?

Vascular health and aging are the most important health care problem in the world today. Healthy aging requires healthy arteries and a healthy heart. Cardio NAD+ is a state-of-the-art solution which uses the most novel ingredients available to help optimize cardiovascular health. As one of the most important systems in your body, we have designed this combination to be synergistic to the many different areas of cardiovascular health while demonstrating cardioprotective effects including the emerging connection between NAD+ and heart health. 

Featured Supportive Benefits: 

  • Improves net NAD+ status by supporting both its synthesis and limiting its degradation 
  • Supports healthy blood pressure 
  • Improves vascular aging and endothelial function
  • Supports healthy fibrinolytic activity and clotting function
  • Promotes healthy circulation and blood flow 
  • Inhibits platelet & red blood cell aggregation
  • Decreases blood viscosity
  • Supports clinical measures of inflammation 
  • Supports healthy blood sugar and insulin levels
  • Inhibits lipid peroxidation
  • Supports healthy lipid metabolism
  • Demonstrated reduction in various independent cardiovascular risk factors

First, we have also included NAD3®, a new and novel ingredient which uses a different approach to manage cardiovascular factors while having positive influences on the hallmarks of aging.  NAD3® is a unique blend of Wasabi japonica extract, theacrine and copper(I)-niacin complex. It turbocharges enzymes that boost the conversion of NAD+ precursors to NAD+ while also suppressing the activity proteins that deplete NAD+.  While you may be familiar with NAD+ supplements for longevity. This product has been designed to also help modulate inflammation and reduce lipids in our blood associated with heart disease. Compared to placebo, at a dose of only 312mg daily, NAD3® lead to significant changes in multiple cardiovascular risk factors (-19%VLDL, -16%LDL, -12%Tot Chol) with a safe, well-tolerated dietary supplement that also demonstrated multiple additional benefits related to healthy aging and cellular longevity.  NAD3® may improve NAD+ status by supporting its synthesis and limiting its degradation, in addition to activating the downstream signaling pathways of longevity, while minimizing the chronic stress of aging. The end result is to try to slow down biological aging by playing both “offense” (amplifying the stress-resilience/ longevity genes), and “defense” (by mitigating the molecular and biochemical hallmarks of aging).  A recent published study demonstrated NAD3® can positively alter molecular markers related to lipid metabolism, cardiometabolic health and hallmarks of aging. NAD3® is a multi-mechanistic solution for healthy aging, mitochondrial performance, cellular longevity.

Second, we have designed ingredient combinations to help with some of the physical components of heart health such as blood pressure and blood viscosity.  For this we have included NSK-SD® (Nattokinase) as an ingredient to help support healthy levels of inflammation, reduce the potential for clots, and to optimize blood pressure backed by over 30 published studies over 25 years of research.   This natural ingredient purified from soybeans has shown to reduce systolic blood pressure by 13.55 points in just 4 weeks. In vitro experiments and human studies suggest that nattokinase may improve blood flow, decrease blood viscosity, reduce the stickiness of red blood cells, and inhibit platelet aggregation. 

Cardio NAD+ also includes AmealPeptide® which was discovered over the course of around 40 years of continuous research into the physiological functions of fermented milk, produced during the process of manufacturing the lactic acid drink CALPIS®.  AmealPeptide® consists of two lactotripeptides - Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP).

Key features include its blood pressure-lowering effects and ability to improve cardiovascular functions. AmealPeptide® has an inhibitory activity against angiotensin converting enzyme (ACE). It works on blood vessels by inhibiting enzymes that cause elevated blood pressure and by stimulating production of nitric oxide (NO), which helps to protect blood vessels. These two peptides have substantial effects on improving vascular endothelial dysfunction, vasodilatation, decreases muscle soreness and improves blood flow throughout the body. 

In addition to this,  a newer version of curcumin called tetrahydrocurcumin (4-HC) as been added. It has been documented that curcumin has many cardiovascular benefits. Tetrahydrocurcumin is more bioavailable and as a result, supports better reductions in inflammation. Studies show that tetrahydrocurcumin yields a significant reduction in serum and liver cholesterol, triglycerides, and free fatty acids while supporting healthy levels of inflammation. It also reduces VLDL and LDL cholesterol levels and is more active than curcumin for antihyperlipidemic effects.

Citrus Bergamot, an aromatic fruit from southern Italy, has been added to the formula.  ​ Bergamot has been shown to support a variety of cardio-metabolic biomarkers such as cholesterol, triglycerides, LDL and HDL in several studies. 

This combination of natural ingredients provides the best protection for one of the largest causes of death in the world by supporting lipids, improving cardiovascular mechanics by optimizing blood pressure and helping resolve systemic inflammation.

AmealPeptide® is a registered trademark of Asahi Soft Drinks Co., Ltd. Tokyo, Japan

NAD3® is patent-pending and under exclusive global distribution by Compound Solutions, Inc.

SK-SD® is a registered trademark of Japan BioScience Laboratory, Co., Ltd.

CurcuPrime® is a registered trademark of NNB Nutrition 

General:

 

  • North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012 Apr 13;110(8):1097-108. doi: 10.1161/CIRCRESAHA.111.246876. PMID: 22499900; PMCID: PMC3366686.
  • Marian AJ, Bhatnagar A, Bolli R, Izpisua Belmonte JC. Introduction to Cardiovascular Aging Compendium. Circ Res. 2018 Sep 14;123(7):737-739. doi: 10.1161/CIRCRESAHA.118.313940. PMID: 30355084.
  • Abdellatif M, Sedej S, Kroemer G. NAD+Metabolism in Cardiac Health, Aging, and Disease. Circulation. 2021 Nov 30;144(22):1795-1817. doi: 10.1161/CIRCULATIONAHA.121.056589. Epub 2021 Nov 29. PMID: 34843394.
  • Matasic DS, Brenner C, London B. Emerging potential benefits of modulating NADmetabolism in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H839-H852. doi: 10.1152/ajpheart.00409.2017. Epub 2017 Dec 22. PMID: 29351465; PMCID: PMC5966770.
  •  

    NAD3®:

    • Roberts, M.D.; La Monica, M.B.; Raub, B.; Sandrock, J.E.; Ziegenfuss, T.N.; Smith, R.; Dwaraka, V.B.; Lopez, H.L. The Effects of a Multi-Ingredient Supplement Containing Wasabia Japonica Extract, Theacrine, and Copper (I) Niacin Chelate on Peripheral Blood Mononuclear Cell DNA Methylation, Transcriptomics, and Sirtuin Activity. Physiologia 20233, 233-246. https://doi.org/10.3390/physiologia3020016
    • Roberts MD, Osburn SC, Godwin JS, Ruple BA, La Monica MB, Raub B, Sandrock JE, Ziegenfuss TN, Lopez HL. Enhance Trial: Effects of NAD3® on Hallmarks of Aging and Clinical Endpoints of Health in Middle Aged Adults: A Subset Analysis Focused on Blood Cell NAD+ Concentrations and Lipid Metabolism. Physiologia. 2022; 2(1):20-31. https://doi.org/10.3390/physiologia2010002
    • Sheng YY, Xiang J, Wang ZS, Jin J, Wang YQ, Li QS, Li D, Fang ZT, Lu JL, Ye JH, Liang YR, Zheng XQ. Theacrine From Camellia kuchaand Its Health Beneficial Effects. Front Nutr. 2020 Dec 17;7:596823. doi: 10.3389/fnut.2020.596823. PMID: 33392238; PMCID: PMC7773691.

    NSK-SD:

    • Kurosawa Y, Nirengi S, Homma T, Esaki K, Ohta M, Clark JF, Hamaoka T. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep. 2015 Jun 25;5:11601. doi: 10.1038/srep11601. PMID: 26109079; PMCID: PMC4479826.
    • Ero MP, Ng CM, Mihailovski T, Harvey NR, Lewis BH. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Altern Ther Health Med. 2013 May-Jun;19(3):16-9. PMID: 23709455.
    • Jensen GS, Lenninger M, Ero MP, Benson KF. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. 2016 Oct 13;9:95-104. doi: 10.2147/IBPC.S99553. PMID: 27785095; PMCID: PMC5066864.

    AmealPeptide® 

    • Boelsma E, Kloek J. Lactotripeptides and antihypertensive effects: a critical review. Br J Nutr. 2009 Mar;101(6):776-86. doi: 10.1017/S0007114508137722. Epub 2008 Dec 5. PMID: 19061526.
    • Cicero AF, Colletti A, Rosticci M, Cagnati M, Urso R, Giovannini M, Borghi C, D'Addato S. Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical Trial. Metab Syndr Relat Disord. 2016 Apr;14(3):161-6. doi: 10.1089/met.2015.0093. Epub 2015 Dec 18. PMID: 26683986.
    • Jäkälä P, Vapaatalo H. Antihypertensive Peptides from Milk Proteins. Pharmaceuticals (Basel). 2010 Jan 19;3(1):251-272. doi: 10.3390/ph3010251. PMID: 27713251; PMCID: PMC3991029.
    • Tomiyama H, Fujii M, Shiina K, Ueda SI, Iwasaki Y, Matsumoto C, Chikamori T. Effects of Lactotripeptide Supplementation on Tele-Monitored Home Blood Pressure and on Vascular and Renal Function in Prehypertension - Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study. Circ Rep. 2019 Oct 2;1(10):438-444. doi: 10.1253/circrep.CR-19-0061. PMID: 33693081; PMCID: PMC7897546.

    Tetrahydrocurcumin:

      • Chen X, Xie Q, Zhu Y, Xu J, Lin G, Liu S, Su Z, Lai X, Li Q, Xie J, Yang X. Cardio-protective effect of tetrahydrocurcumin, the primary hydrogenated metabolite of curcumin in vivo and in vitro: Induction of apoptosis and autophagy via PI3K/AKT/mTOR pathways. Eur J Pharmacol. 2021 Nov 15;911:174495. doi: 10.1016/j.ejphar.2021.174495. Epub 2021 Sep 20. PMID: 34555398.

     

  • Lai CS, Ho CT, Pan MH. The Cancer Chemopreventive and Therapeutic Potential of Tetrahydrocurcumin. Biomolecules. 2020 May 29;10(6):831. doi: 10.3390/biom10060831. PMID: 32486019; PMCID: PMC7356876.
  • Aggarwal BB, Deb L, Prasad S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. Molecules. 2014 Dec 24;20(1):185-205. doi: 10.3390/molecules20010185. PMID: 25547723; PMCID: PMC6272158.
  •  Xiang L, Nakamura Y, Lim YM, Yamasaki Y, Kurokawa-Nose Y, Maruyama W, Osawa T, Matsuura A, Motoyama N, Tsuda L. Tetrahydrocurcumin extends life span and inhibits the oxidative stress response by regulating the FOXO forkhead transcription factor. Aging (Albany NY). 2011 Nov;3(11):1098-109. doi: 10.18632/aging.100396. PMID: 22156377; PMCID: PMC3249455.
  •  

    Citrus Bergamot:

    • Nauman MC, Johnson JJ. Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers. Integr Food Nutr Metab. 2019 Mar;6(2):10.15761/IFNM.1000249. doi: 10.15761/IFNM.1000249. Epub 2019 Feb 28. PMID: 31057945; PMCID: PMC6497409.
    • Huang Y, Tocmo R, Nauman MC, Haughan MA, Johnson JJ. Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells. Nutrients. 2021 Sep 10;13(9):3156. doi: 10.3390/nu13093156. PMID: 34579033; PMCID: PMC8469228.

    You also Viewed

    Customer Reviews

    Be the first to write a review
    0%
    (0)
    0%
    (0)
    0%
    (0)
    0%
    (0)
    0%
    (0)